Precigen completes BLA submission for PRGN-2012 and raises $79M in private placement

PRECIGEN, INC.

Submitted BLA to FDA for PRGN-2012 (RRP), requesting priority review; 60-day review period to determine acceptance.
Phase 1/2 pivotal study: >50% of patients achieved Complete Response; >85% had fewer surgeries in year post-treatment.
Raised $79M gross from sale of 8% Series A Convertible Perpetual Preferred Stock and warrants to purchase 52.7M shares at $0.75.
Investors include Randal Kirk, Patient Capital Management, Bill Miller; proceeds for working capital and general corporate purposes.
Cash runway extends into 2026, beyond potential commercial launch in H2 2025 if PRGN-2012 is approved.

item 1.01 item 8.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.